Intersect ENT, Inc. (XENT) Analysts See $-0.17 EPS; Last Week Assura Plc (LON:AGR) Analysts

February 12, 2018 - By Louis Casey

Among 3 analysts covering Assura Group Ltd (LON:AGR), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Assura Group Ltd had 41 analyst reports since August 20, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Thursday, January 18. Liberum Capital maintained Assura Plc (LON:AGR) rating on Tuesday, July 18. Liberum Capital has “Buy” rating and GBX 68 target. The firm earned “Buy” rating on Tuesday, August 1 by Liberum Capital. The stock of Assura Plc (LON:AGR) earned “Hold” rating by Liberum Capital on Friday, November 25. The firm has “Hold” rating by Peel Hunt given on Tuesday, November 22. As per Tuesday, May 23, the company rating was maintained by Liberum Capital. The stock has “Hold” rating by Peel Hunt on Wednesday, October 4. Liberum Capital maintained Assura Plc (LON:AGR) on Wednesday, October 14 with “Hold” rating. Liberum Capital maintained it with “Hold” rating and GBX 60 target in Wednesday, May 18 report. On Monday, October 3 the stock rating was maintained by Liberum Capital with “Hold”. See Assura Plc (LON:AGR) latest ratings:

01/02/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 68.00 New Target: GBX 66.00 Maintain
18/01/2018 Broker: Jefferies Rating: Buy New Target: GBX 70.00 Maintain
08/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 68.00 New Target: GBX 68.00 Maintain
29/11/2017 Broker: Jefferies Rating: Buy New Target: GBX 66.00 Initiates Starts
21/11/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 68.00 New Target: GBX 68.00 Maintain
16/11/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 55.00 New Target: GBX 57.00 Maintain
16/11/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 68.00 New Target: GBX 68.00 Maintain
10/11/2017 Broker: Peel Hunt Rating: Hold New Target: GBX 55.00 Maintain
04/10/2017 Broker: Peel Hunt Rating: Hold Maintain
04/10/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 68.00 New Target: GBX 68.00 Maintain

Analysts expect Intersect ENT, Inc. (NASDAQ:XENT) to report $-0.17 EPS on February, 27.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.17 EPS. After having $-0.15 EPS previously, Intersect ENT, Inc.’s analysts see 13.33% EPS growth. The stock increased 1.99% or $0.7 during the last trading session, reaching $35.85. About 292,084 shares traded or 2.03% up from the average. Intersect ENT, Inc. (NASDAQ:XENT) has risen 79.98% since February 12, 2017 and is uptrending. It has outperformed by 63.28% the S&P500.

The stock increased 1.47% or GBX 0.875 during the last trading session, reaching GBX 60.375. About 322,284 shares traded. Assura Plc (LON:AGR) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Assura Plc is a publicly owned real estate investment trust. The company has market cap of 1.44 billion GBP. It engages in the ownership and development of a diversified portfolio of primary health care properties, and the provision of related services. It has a 8.05 P/E ratio.

Among 9 analysts covering Intersect ENT (NASDAQ:XENT), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Intersect ENT had 20 analyst reports since August 17, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, August 21 by Piper Jaffray. The stock of Intersect ENT, Inc. (NASDAQ:XENT) earned “Buy” rating by Canaccord Genuity on Monday, August 17. Canaccord Genuity maintained the shares of XENT in report on Wednesday, September 13 with “Buy” rating. As per Thursday, October 1, the company rating was maintained by Canaccord Genuity. On Monday, October 16 the stock rating was maintained by Canaccord Genuity with “Buy”. Canaccord Genuity maintained Intersect ENT, Inc. (NASDAQ:XENT) on Wednesday, December 6 with “Buy” rating. Piper Jaffray maintained it with “Overweight” rating and $30 target in Tuesday, September 29 report. The firm has “Hold” rating given on Thursday, October 6 by Deutsche Bank. Canaccord Genuity maintained Intersect ENT, Inc. (NASDAQ:XENT) rating on Thursday, January 4. Canaccord Genuity has “Buy” rating and $43.0 target. JP Morgan downgraded Intersect ENT, Inc. (NASDAQ:XENT) on Wednesday, November 2 to “Neutral” rating.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $1.06 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>